AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00537446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
Study NCT00537446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
Study NCT00280566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
Study NCT00280566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Oral Capsule
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
Study NCT01502644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Daily dosage up to 120 mg
Study NCT01502644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Daily dosage up to 90 mg immediate release or 180 mg extended release
Study NCT01502644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching oxycodone, placebo-matching morphine
Study NCT02827058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G25 pencil point needle
Study NCT02827058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G27 pencil point needle
Study NCT02617316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barefoot
Description: barefoot running test was 20 minutes.
Study NCT02617316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In shoes
Description: In shoes test was 20 minutes.
Study NCT00057746 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation, 2.5 Gy fx
Description: Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
Study NCT00057746 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation, 2.0 Gy fx
Description: Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
Study NCT00057746 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation, 1.5 Gy fx
Description: Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
Study NCT03065556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Solution
Description: Topical solution containing active drug
Study NCT03065556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Topical solution containing no active drug
Study NCT02002234 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemicraniotomy
Description: Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
Study NCT02002234 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
Study NCT01721590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: Tongxinluo,3 capsules/time 3times/day for 1 year
Study NCT01721590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules/time，3times/day for 1 year
Study NCT04090567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT04090567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO
Study NCT04090567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02277496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolkit Intervention
Description: The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
Study NCT00393939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
Study NCT00393939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
Study NCT05611086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Subjects in treatment group will be given capsules containing 600 mg of NAC
Study NCT05611086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects in the control group will be given capsules containing placebo (lactose)
Study NCT00748956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose NPY
Description: 50nmol, administered intranasally
Study NCT00748956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose NPY
Description: 100nmol administered intranasally
Study NCT00748956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator (0nmol)) administered intranasally
Study NCT01539382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation intervention
Description: The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
Study NCT00449293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard cognitive behavioral therapy
Description: Standard therapy to help participants with smoking cessation.
Study NCT00449293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
Study NCT01606085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HF DM self care
Description: Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
Study NCT01606085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: CAB tablets were available as film coated tablets for oral administration.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension (CAB LA)
Description: CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir Injectable Suspension (CAB LA)
Description: CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: RPV was administered as tablets for oral administration.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension (RPV LA)
Description: RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine Injectable Suspension (RPV LA)
Description: RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
Study NCT04542070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIKTARVY Tablets (BIK)
Description: BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
Study NCT02510846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive educative management
Description: 5 hours a week
Study NCT02510846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive educative management
Description: 5 hours a week
Study NCT02988063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam (PEM)
Description: Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Study NCT03917134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalosporin + Metronidazole Vaginal
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
Study NCT03917134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cephalosporin + Placebos
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
Study NCT00961324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
Study NCT00961324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
Study NCT04463381 — intervention group
Intervention type: PROCEDURE
Intervention: choledochotomy techniques during LCBDE
Study NCT03244228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution
Study NCT03244228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Concentrate
Description: Matching placebo
Study NCT00808938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: Magnetic Seizure Therapy
Study NCT04631497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: test
Description: 1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE
Study NCT00647192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 mg per day
Study NCT00647192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg per day
Study NCT01234623 — intervention group
Intervention type: OTHER
Intervention: UCS eyedrops
Description: 1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
Study NCT03697200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APA
Description: Light touch using vaccaria seeds on specific points of the ear
Study NCT03697200 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham APA control
Description: Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
Study NCT03697200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education control
Description: Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
Study NCT04612634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
Study NCT04612634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
Study NCT04612634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS
Description: Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
Study NCT04961892 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment
Description: Anatomical contraction and termination reconstruction of the lateral ligament
Study NCT04961892 — intervention group
Intervention type: PROCEDURE
Intervention: conservative treatment
Description: Rehabilitation intervention training
Study NCT02985242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin film-coated tablet
Study NCT02985242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet
Study NCT02985242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo
Description: Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
Study NCT02985242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride placebo
Description: Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
Study NCT00627679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalation Suspension
Description: Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study NCT01965431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 placebo
Study NCT01965431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir placebo
Study NCT01965431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: Medium dose oral administration
Study NCT01965431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Avalox®)
Study NCT00627679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study NCT00627679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 intermediate dose
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study NCT02391714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
Study NCT03890835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy.
Description: Pulpotomy using MTA.
Study NCT00538499 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl citrate
Study NCT00538499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrocloride
Study NCT00538499 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: videothoracoscopy
Study NCT03890835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine Pulpotomy
Description: Pulpotomy using Biodentine
Study NCT02724423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL-1
Study NCT00627679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study NCT00807040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral Valve Repair with Annuloplasty
Description: The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
Study NCT00807040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral Valve Replacement
Description: Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
Study NCT00833391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open label
Description: This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
Study NCT04260815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
Study NCT04260815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
Study NCT00409292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally daily for as long as the participant continues to receive a benefit.
Study NCT01430065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT01430065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT04528758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodamine 6G
Description: Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
Study NCT04528758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhodamine 6G
Description: Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
Study NCT01918475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin 0.1 mg single dose is intravenously administered
Study NCT01918475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1ml of NaCl 0.9% is administered intravenously
Study NCT03677856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Description: Type of anaesthesia
Study NCT03677856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: Type of anaesthesia
Study NCT01276080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg tablets